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ABSTRACT Vivax malaria remains one of the most serious and neglected tropical
diseases, with 132 to 391 million clinical cases per year and 2.5 billion people at risk
of infection. A vaccine against Plasmodium vivax could have more impact than any
other intervention, and the use of a vaccine targeting multiple antigens may result
in higher efﬁcacy against sporozoite infection than targeting a single antigen. Here,
two leading P. vivax preerythrocytic vaccine candidate antigens, the P. vivax circum-
sporozoite protein (PvCSP) and the thrombospondin-related adhesion protein
(PvTRAP) were delivered as a combined vaccine. This strategy provided a dose-
sparing effect, with 100% sterile protection in mice using doses that individually
conferred low or no protection, as with the unadjuvanted antigens PvTRAP (0%) and
PvCSP (50%), and reached protection similar to that of adjuvanted components. Efﬁ-
cacy against malaria infection was assessed using a new mouse challenge model
consisting of a double-transgenic Plasmodium berghei parasite simultaneously ex-
pressing PvCSP and PvTRAP used in mice immunized with the virus-like particle
(VLP) Rv21 previously reported to induce high efﬁcacy in mice using Matrix-M adju-
vant, while PvTRAP was concomitantly administered in chimpanzee adenovirus and
modiﬁed vaccinia virus Ankara (MVA) vectors (viral-vectored TRAP, or vvTRAP) to
support effective induction of T cells. We examined immunity elicited by these vac-
cines in the context of two adjuvants approved for human use (AddaVax and Matrix-
M). Matrix-M supported the highest anti-PvCSP antibody titers when combined with
Rv21, and, interestingly, mixing PvCSP Rv21 and PvTRAP viral vectors enhanced im-
munity to malaria over levels provided by single vaccines.
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Vivax malaria remains one of the world’s most neglected tropical diseases (1, 2), andit is considered to be responsible for 132 to 391 million clinical cases per year with
2.5 billion people at risk of infection (3), mainly in Southeast Asia and Latin America (4).
An efﬁcacious vaccine against Plasmodium vivax or Plasmodium falciparum could have
more impact in reducing or eliminating this disease than any other intervention (5, 6).
However, parasite diversity and a complex life cycle are major obstacles hampering
vaccine development, and it is considered that an efﬁcacious vaccine may require
harnessing cellular and humoral immune responses against multiple antigens (7). This
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view has prompted an evaluation of the efﬁcacy of multiple antigens using various
vaccine platforms against infection by Plasmodium berghei (8) and P. falciparum (9).
The leading vaccine candidates against P. vivax are the preerythrocytic antigen P.
vivax circumsporozoite protein (PvCSP) (2, 10, 11) and the blood stage antigen Duffy
binding protein (12, 13), both having completed clinical trials (https://clinicaltrials.gov/
show/NCT01816113) (10). The low levels of protective efﬁcacy of the PvCSP vaccine
candidate VMP001 has prompted the development of improved strategies consisting of
a particulate circumsporozoite antigen delivered as a virus-like particle (VLP), CSV-S,S
(14), and Rv21 (15). The thrombospondin-related adhesion protein (TRAP) is another
preerythrocytic vivax malaria antigen that has shown promise in a recent preclinical
study (16). Effective preerythrocytic vivax vaccines, unlike blood stage approaches,
would have the potential to prevent or eliminate the quiescent liver stage forms known
as hypnozoites, which cause relapse long after a primary infection (17) and are among
the greatest obstacles to malaria eradication (2).
For P. falciparum malaria, similar vaccine candidates based on CSP (PfCSP) and
PfTRAP have a longer track record of development than their P. vivax counterparts, but,
unfortunately, both have reported suboptimal protection in humans (18). The leading
RTS,S/AS01 falciparum vaccine candidate, Mosquirix, has completed phase III clinical
trials, but despite its approval by the European Medicines Agency for childhood
immunization, it did not achieve an endorsement by the WHO, thus limiting its future
integration into existing malaria control programs (19). The most recent results indicate
that three vaccine doses of RTS,S/AS01 protected 37% of infants (20) and 47% of
children (21) against severe malaria. In a recent phase IIa clinical trial, PfTRAP delivered
in a chimpanzee adenovirus 63 and modiﬁed virus Ankara (ChAd63-MVA) prime-boost
regime induced sterile protection in 21% of human volunteers (22).
Efforts to improve the efﬁcacy of malaria vaccines have led to the development of
vaccine approaches in which not a single antigen is targeted; instead multiple antigens,
either from the same life cycle stage or from multiple stages, are targeted. In this
regard, vaccine approaches targeting the two leading preerythrocytic vaccine candi-
dates, CSP and TRAP, show enhanced protection in animal models of malaria (8, 23)
compared to vaccines targeting a single antigen. A recent phase IIa clinical trial
evidenced an enhancement in protective efﬁcacy against challenge with P. falciparum
using a combination of RTS,S/AS01B with recombinant viral vectors ChAd63 and MVA
expressing ME-TRAP (where ME is multiepitope) (9), thus supporting this combination
strategy.
A model of enhanced protection using a vaccine targeting CSP and TRAP was
suggested by Bauza et al. (8), using a two-stage approach, whereby antibodies (Abs) to
P. berghei CSP (PbCSP) limited the number of P. berghei sporozoites reaching the liver,
followed by PbTRAP-speciﬁc CD8 T cells destroying a reduced number of infected
hepatocytes. Viral vectors encoding the target antigen have been shown to elicit high
numbers of CD8 T cells, particularly when adenovirus-modiﬁed vaccinia virus Ankara
(Ad-M or viral-vectored TRAP [vvTRAP]) is used in heterologous prime-boost regimens
(16, 22, 24). Thus, viral vectors are used here to deliver the PvTRAP antigen (vvTRAP) to
stimulate cytotoxic T-lymphocyte (CTL) responses, whereas the VLP Rv21 was used to
generate high titers of anti-CSP antibodies (Abs). Rv21 VLP is based on the hepatitis B
surface antigen (HepBsAg), and it has been shown to be highly efﬁcacious against a
sporozoite challenge, providing complete, sterile protection following two doses of
Rv21 in Matrix-M adjuvant (15).
While vaccination using two antigens would be expected to provide enhanced
protection against infection, the possibility remains of inducing antigenic interference
due to the use of adjuvants or platforms to deliver the antigens. The phenomenon of
antigenic interference may hamper the success of any combination vaccine due to the
decrease in antibody or cytotoxic T-cell responses against any of the vaccine antigens,
which has been observed in studies where two or more antigens have been combined
(8, 25). Here, we aimed to augment the efﬁcacy of known vivax preerythrocytic vaccines
by combining CSP and TRAP using two different vaccine platforms for each antigen and
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two adjuvants suitable for human use: (i) AddaVax, a squalene-based oil-in-water
nanoemulsion with a formulation similar to that of MF59 (26), and (ii) Matrix-M, a
nanoparticle saponin-based adjuvant (27, 28).
RESULTS
In order to assess in vivo protective efﬁcacy of the different P. vivax vaccine
platforms, we developed a rodent challenge model consisting of a double-chimeric P.
berghei parasite line that was generated by replacing the Pbtrap with the Pvtrap gene
in a single chimeric line in which the Pbcsp gene had initially been replaced by the
VK210 allele of Pvcsp. The single chimeric line, PbANKA-PvCSP-VK210(r)PbCSP (line
2196cl1), was developed through the use of gene insertion/marker out (GIMO) trans-
fection technology as described previously (15) and is free of a drug-selectable marker.
In addition, the resulting parasite contains the green ﬂuorescent protein (GFP)-
luciferase fusion gene as a reporter. The absence of a drug-selectable marker permitted
the replacement of the Pbtrap gene with the Pvtrap gene in parasites of the PbANKA-
PvCSP-VK210(r)PbCSP line in a single transfection experiment using a trap replacement
construct described previously (16). This construct contains a synthetic trap allele
composed of the protein-coding sequence of P. vivax TRAP (NCBI accession number
XM_001614097) from the Salvador I strain that was codon optimized for expression in
P. berghei using GeneOptimizer software. Transfection of PbANKA-PvCSP-VK210(r)PbCSP
parasites with the trap replacement construct and positive selection with pyrimetham-
ine resulted in selection of double-chimeric parasites [PbANKA-PvCSP-VK210(r)PbCSP-
PvTRAP(r)PbTRAP], referred to as PvCSP-VK210/PvTRAP parasites (see Fig. S1 in the
supplemental material). Integration of the Pvcsp and Pvtrap genes in PvCSP/PvTRAP
was conﬁrmed by diagnostic Southern analysis of chromosomes separated by pulsed-
ﬁeld gel electrophoresis and diagnostic PCR on genomic DNA (gDNA) (Fig. S2A and B).
PvCSP-VK210/PvTRAP parasites are double-chimeric P. berghei parasites that do not
contain the P. berghei csp or trap gene coding sequence (CDS) but express both P. vivax
csp-VK210 and the P. vivax trap CDS under the control of the P. berghei csp and trap
equivalent regulatory sequences and is drug-selectable marker free.
We next assessed the ability of the double-replacement chimeric parasites to
produce oocysts and sporozoites since replacing the endogenous csp and trap genes
with the P. vivax orthologs could alter these characteristics. Oocyst and sporozoite
production in Anopheles stephensi of PvCSP-VK210/PvTRAP was similar to oocyst and
sporozoite production of wild-type (WT) P. berghei (Fig. 1A and B). The infectivity of
sporozoites of both transgenic parasites was assessed by determination of the prepat-
ent period (i.e., the time to 1% parasitemia) after intravenous injection of 2,000
sporozoites in the tail vein of BALB/c mice. All mice developed blood parasitemia, and
the times to reach 1% parasitemia were not different between WT and PvCSP-VK210/
PvTRAP parasites (Fig. 1C). Expression of the Pvcsp-VK210 and Pvtrap proteins in
PvCSP-VKCSP/PvTRAP sporozoites was conﬁrmed by immunoﬂuorescence microscopy
of sporozoites using anti-PvCSP monoclonal antibodies to the repeat region of the
PvCSP-VK210 and polyclonal anti-PvTRAP antibodies. PbTRAP was present only in
wild-type sporozoites and not in PvCSP-VK210/PvTRAP sporozoites (Fig. 1D). These
results demonstrate that the double-chimeric PvCSP-VK210/PvTRAP parasites produce
infectious sporozoites, which are able to complete full liver stage development in mice.
Next, we used these chimeric PvCSP-VK210/PvTRAP sporozoites as a challenge
model by infecting immunized mice and assessing protective efﬁcacy of various
combinations of PvCSP-VK210 and PvTRAP vaccines.
Combining vvTRAP with vivax CSP enhances protection compared to that of
either component alone. The prime-boost using the malaria vaccine candidate TRAP
(thrombospondin-related adhesion protein), expressed by adenoviral or modiﬁed vac-
cinia virus Ankara viral vectors (viral-vectored TRAP, or vvTRAP), combined with a
regime consisting of adenovirus expressing CSP followed by a protein boost (Ad-P) CSP
has previously been tested, showing enhancement in protection against a challenge
with wild-type P. berghei compared to use of either antigen alone (8). Here, we applied
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a similar vaccination strategy using P. vivax antigens to assess protective efﬁcacy
against a challenge with the double-transgenic PvCSP-VK210/PvTRAP P. berghei de-
scribed above; BALB/c mice were vaccinated as shown in Fig. 2A. High frequencies of
ex vivo gamma interferon (IFN-) enzyme-linked immunosorbent spot (ELISpot) re-
sponses were induced against an immunodominant PvTRAP CD8 epitope (Fig. 2B).
Similarly, high titers of anti-CSP antibodies (Fig. 2C) were obtained, and no signiﬁcant
differences in either antibody titers or T-cell frequencies were observed between a
single- and a double-component vaccine. No vaccine approach conferred sterile pro-
tection to any mouse following a parasite challenge (Fig. 2D). However, the combina-
tion of vvTRAP and Ad-P CSP, vvTRAP plus (vvCSP-PvCSP), signiﬁcantly enhanced
protective efﬁcacy, measured as an increase in the time taken to reach 1% blood stage
parasitemia compared to results with either component vaccine alone, conﬁrming that,
as with wild-type P. berghei, the combination of vivax vvTRAP and CSP antigens
enhances protection against a sporozoite challenge even when equal magnitudes of
adaptive humoral and cellular immune responses were induced, indicating the advan-
tage of using two different vaccine candidates simultaneously for vaccination. To
determine if higher levels of protection could be obtained, we next substituted vvCSP
and PvCSP protein for Rv21, a P. vivax CSP preerythrocytic vaccine based on a hepatitis
B virus-like particle (VLP), which has recently been shown to induce high levels of
protective efﬁcacy against a challenge with transgenic sporozoites expressing vivax CSP
(15).
FIG 1 Parasite ﬁtness and phenotype characterization of a double-transgenic P. berghei parasite expressing Plasmodium vivax CSP-VK210 and TRAP. The ability
of the PvCSP-VK210/PvTRAP double-transgenic parasite to develop in the invertebrate host was evaluated. (A) Ten days after feeding on infected mice,
mosquito midguts were obtained, and oocysts were enumerated for both wild-type and PvCSP-VK210/PvTRAP 2207 cl3m0cl1 parasites. (B) Twenty-one days
after feeding, salivary gland sporozoites were extracted and enumerated, and the numbers of sporozoites per mosquito was compared between wild-type and
PvCSP-VK210/PvTRAP 2207 cl3m0cl1-infected Anopheles stephensi. Data are shown as means with standard deviations, and P values from t tests. (C) The ability
of 2207 cl3m0cl1 to infect vertebrate hosts was evaluated by injecting salivary gland sporozoites into naive BALB/c mice (n 6) and monitoring for blood stage
infection. Outcome is shown as the time to reach 1% blood stage parasitemia. A Mantel-Cox test was performed between groups. (D) Transgenic salivary gland
sporozoites were stained with anti-PvCSP-VK210, polyclonal anti-PvTRAP, or with serum from vaccinated mice with ChAd63-MVA expressing PvTRAP or PbTRAP.
Alexa Fluor 488-labeled anti-mouse IgG and Hoechst-33342 (nuclear staining) were also included for the assay. As a control, wild-type (WT) P. berghei sporozoites
were stained with the same antibodies. Merged images of the different channels are shown for both transgenic and WT P. berghei stained images.
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Effect on immunogenicity of a combination of vvTRAP, Rv21, and two adju-
vants. We investigated various approaches to adjuvant immune responses to the P.
vivax vaccine candidates CSP and TRAP. To this end, BALB/c mice were vaccinated with
combinations of vvTRAP and Rv21 in the presence or absence of two adjuvants suitable
for human use (Table 1). The combination consisted of a mixture of TRAP viral vectors
(vvTRAP) delivered as an adenovirus expressing vivax TRAP with Rv21 presenting CSP
used for priming and followed by a boost 8 weeks later using a combination of
MVA-TRAP mixed with Rv21. Of interest, we observed a signiﬁcant adjuvanting effect
on the vivax CSP antibodies just by mixing vvTRAP with Rv21 at the doses indicated in
Table 1 in the absence of any chemical adjuvant. This was evident both after a prime
with adenovirus plus Rv21 and after a boost with MVA plus Rv21 and for a follow-up
period of 275 days (Fig. 3A). Next, we studied the effect of adding two clinically relevant
adjuvants to Rv21 or to the mixture of Rv21 plus vvTRAP (Rv21vvTRAP). We ﬁrst
tested AddaVax, a squalene-based oil-in-water nanoemulsion with a formulation similar
to that of MF59 (26). AddaVax-adjuvanted Rv21 increased signiﬁcantly the anti-PvCSP
titers after both a prime and homologous Rv21 prime/boost regimens compared to
results with Rv21 alone. When AddaVax was added to the mixture of Rv21vvTRAP, a
signiﬁcant increase in titers was seen after an MVA boost compared to results using
FIG 2 Immunogenicity and protective efﬁcacy of a combination P. vivax CSP-VK210 with adenoviral or MVA viral vectors expressing P. vivax TRAP (vvTRAP). (A)
Inbred female BALB/c mice (n 7 to 8/group) were primed with PvCSP-VK210 viral vector (vv) followed by the PvCSP protein (vvCSP-PvCSP), ChAd63-MVA viral
vector expressing PvTRAP (vvTRAP), or their combination (vvTRAPvvCSP-PvCSP). (B) Two weeks postboost ex vivo IFN- ELISpot responses were measured
upon restimulation of whole-blood PBMCs with three subpools of peptides representing the full-length PvTRAP. Values are means and standard errors of the
means. (C) An endpoint titer ELISA was done to quantify anti-PvCSP-VK210 antibodies. Bars indicate median responses. (D) Two weeks after the last vaccination,
animals were challenged by intravenous injection of 2,000 double-transgenic P. berghei PvCSP-VK210 and PvTRAP sporozoites. Blood stage infection was
recorded over three consecutive days starting at day 5 postchallenge, and a linear regression model predicting time to 1% blood stage parasitemia for individual
animals was applied, showing a signiﬁcant delay in the vvTRAPvvCSP-PvCSP group that received a combination vaccine compared to time for the other
treatment groups. Values are means and standard errors of the means. *, P  0.05; **, P  0.01 (Mann-Whitney test comparing two groups).
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Rv21 with AddaVax alone (Fig. 3B). This trend continued for up to 150 days, a time
when responses became similar in both groups and remained comparable until the end
of the study. Additionally, we tested Matrix-M, a saponin-based adjuvant (27, 28) that
has been shown to enhance Rv21 immunity against a sporozoite challenge (15). As
expected, Matrix-M signiﬁcantly enhanced the anti-PvCSP responses elicited by Rv21
compared to those of the group with no adjuvant. However, the inclusion of viral
vectors to the mixture resulted in a decrease in PvCSP-speciﬁc antibodies, which was
evident at various time points after the prime or after the boost. The antigenic
interference effect of viral vectors with Matrix-M appeared to be temporary as beyond
150 days postprime, anti-CSP titers in both groups receiving Matrix-M adjuvants were
similar (Fig. 3C). Mixing vvTRAP with Rv21 signiﬁcantly increased the IgG2a/IgG1 ratio,
and the use of adjuvants also contributed to enhance this ratio in the absence of
adjuvants (Fig. 3D). TRAP-speciﬁc CD8 responses induced by viral vectors did not
show major differences in the presence or absence of adjuvants, with the exception of
a decrease in IFN- released by CD8 T cells in the Matrix-M group, measured in an ex
vivo IFN- ELISpot assay after a boost with a mixture (Fig. 3E). This conﬁrms recent
observations made in our laboratory (29).
Efﬁcacy of a preerythrocytic vivax vaccine is increased using a bivalent vaccine
consisting of vvTRAP and PvCSP in VLPs. The initial results indicating an adjuvant
effect on P. vivax CSP by the use of a combination of viral vectors, virus-like particles
(VLPs), Matrix-M, and AddaVax prompted us to investigate if the increased antibody
titers resulted in enhanced protective efﬁcacy against malaria infection. To this end, we
challenged vaccinated mice with our newly developed chimeric PvCSP-VK210/PvTRAP
sporozoites (Fig. 4). Unadjuvanted bivalent vaccines consisting of vvTRAP, mixed with
only 1.5 g of Rv21 VLP presenting PvCSP on its surface, protected 100% of the
challenged mice, providing sterile efﬁcacy with no signs of parasitemia for up to 20
days postchallenge. Inclusion of Matrix-M and AddaVax in the formulation retained the
high protective levels of combined vaccines (Fig. 4A). Importantly, removing vvTRAP
from the vaccine composition still yielded 100% sterile efﬁcacy in Rv21 plus Matrix-M,
while there was a trend toward reduction of efﬁcacy in Rv21 plus AddaVax on a
challenge (83.3% protection with AddaVax versus 100% with Matrix-M; P  0.36) under
conditions where only 50% of the mice were sterilely protected after vaccination with
unadjuvanted Rv21 (Fig. 4B). In contrast, prime/boost vaccination with only vvTRAP did
not protect mice against a sporozoite challenge, regardless of the presence or absence
of adjuvants (Fig. 4C). Our results indicate a dose-sparing effect of the vaccines by
administering Rv21 combined with either vvTRAP or adjuvants to enhance immunity
against malaria without the need of increasing vaccine doses and open a possibility for
the use of the combination as a fractional dose while retaining protection against
malaria. Finally, we investigated if a protein in adjuvant had similar effects on protec-
tion and injected vivax CSP protein (pPvCS) in Matrix-M. Sterile protective efﬁcacy was
TABLE 1 Vaccination regimes using viral vectors expressing TRAP (vvTRAP) and Rv21 in
BALB/c mice
Vaccine regimen (adjuvant)a
Prime Boost
Rv21-CSP
(g)
Ad-PvTRAP
(IU)
Rv21-CSP
(g)
MVA-PvTRAP
(PFU)
Rv21  vvTRAP 1.5 1  108 1.5 1  107
Rv21 1.5 1.5
vvTRAP 1  108 1  107
Rv21  vvTRAP (AddaVax) 1.5 1  108 1.5 1  107
Rv21 (AddaVax) 1.5 1.5
vvTRAP (AddaVax) 1  108 1  107
Rv21  vvTRAP (Matrix-M) 1.5 1  108 1.5 1  107
Rv21 (Matrix-M) 1.5 1.5
vvTRAP (Matrix-M) 1  108 1  107
aAdjuvant, where present, was used in both prime and boost. For all regimens, the prime-boost interval was
8 weeks.
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FIG 3 Adjuvanticity in a combination of Rv21 P. vivax CSP VLP with adenovirus and modiﬁed vaccinia Ankara
viral vectors expressing P. vivax TRAP (vvTRAP). Inbred BALB/c mice (n  6 per group) were vaccinated with
combinations of CSP and vvTRAP as described in Table 1. Kinetics analysis of anti-CSP antibodies, measured by
ELISA at the indicated time points, was determined with or without coadministration of vvTRAP. (A) Effect of
the coadministration of Rv21 (PvCSP) with vvTRAP without addition of adjuvants. (B) Effect of AddaVax on
anti-PvCSP antibodies induced by Rv21 alone or by Rv21vvTRAP. (C) Effect of Matrix-M on anti-PvCSP
antibodies induced by Rv21 alone or by Rv21vvTRAP. (D) IgG2a/IgG1 ratios in BALB/c mice using Rv21 with
or without vvTRAP and adjuvants. (E) Effect of Rv21, AddaVax, and Matrix-M on ex vivo IFN- responses against
PvTRAP in mice. t tests were used for statistical analyses. *, P 0.05; **, P 0.01; ***, P 0.001; ****, P 0.0001.
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FIG 4 Protective efﬁcacy against a transgenic sporozoite challenge using a combination of the Rv21 and
vvTRAP, in the presence of Matrix-M or AddaVax adjuvants. Inbred BALB/c mice (n  6 per group)
vaccinated with Rv21 and/or vvTRAP as described in Table 1 were challenged by intravenous adminis-
tration of transgenic P. berghei PvCSP-VK210/PvTRAP double-replacement parasites using a stringent
challenge with 2,000 sporozoites. (A) Efﬁcacy of a vaccine consisting of Rv21 combined with either
vvTRAP or of vvTRAP plus the adjuvant Matrix-M (MM) or AddaVax (Add). (B) Efﬁcacy of Rv21 in the
presence of chemical adjuvants. (C) Efﬁcacy of a prime-boost vaccination regimen using vvTRAP. (D)
Efﬁcacy of a P. vivax CSP protein in combination with vvTRAP and Matrix-M adjuvants.
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achieved in only 33% of the vaccinated mice (Fig. 4D) in contrast to 100% of protection
elicited by Rv21 in Matrix-M, stressing the advantage of using a VLP over a soluble
antigen. A summary of the survival efﬁcacy for all groups is presented in Table 2.
A combination of Rv21 VLP and viral vectors requires vivax antigens in both
platforms to enhance protective efﬁcacy against a sporozoite challenge. In the
experiments described in the sections above, anti-PvCSP antibody responses induced
by injection of 1.5 g of Rv21 were adjuvanted by coimmunization with vvTRAP. The
adjuvanting effect, unless properly controlled for, would make the interpretation of
enhancement of protection from Rv21 and vvTRAP coadministration difﬁcult as it
would not be clear if any enhancement in protection derived from the increased
breadth of response to multiple antigens or merely from an improved immunogenicity
to PvCSP titers resulting from inclusion of vvTRAP in the vaccine formulation. To this
end, lower doses of 1 g of Rv21 were mixed with viral vectors expressing an unrelated
Trypanosoma cruzi antigen, Tc24 (30), while a control group received vvTRAP mixed
with R21 presenting P. falciparum CSP (Fig. 5A) (31). This resulted, as desired, in identical
anti-CSP titers in the Rv21 and Rv21vvTRAP groups and identical TRAP-speciﬁc
ELISpot assay responses in the vvTRAP and Rv21vvTRAP groups, thus eliminating the
possibility that an enhancement of protection in the Rv21vvTRAP group compared to
protection of the single-component groups was due to vvTRAP enhancing antibody
responses to PvCSP (Fig. 5C and D). Complete protection was achieved only in the
group in which Rv21 and vvTRAP were combined (Fig. 5B). In contrast, when Rv21 was
mixed with viral vectors expressing an unrelated Chagas Tc24 antigen (vvControl), only
50% of the mice were completely protected, and no sterile protection was afforded
upon vaccination with vvTRAP mixed with R21 presenting P. falciparum CSP.
DISCUSSION
Here, it is demonstrated that immunity against malaria using parasites expressing P.
vivax antigens is enhanced by a combination of two preerythrocytic vaccine candidates,
PvCSP and PvTRAP. This is achieved in mice using a newly developed double-transgenic
P. berghei parasite in which the endogenous PbCSP and PbTRAP were replaced by their
P. vivax homologues. Our initial observations using a combination of a P. vivax CSP
protein with vvTRAP resulted in suboptimal protection against a sporozoite challenge
with the double-transgenic parasite. Importantly, when the CSP protein was replaced
with the virus-like particle (VLP) Rv21, 100% protection was obtained even in the
absence of any adjuvant. Our results open an opportunity to replace an adjuvant by
viral vectors expressing other malaria antigens to enhance protective immunity
through the improvement of immune responses or by targeting additional malaria
antigens. This is important due to the limited number of adjuvants that are currently
available for human use (32). Greater availability of immunostimulatory alternatives
TABLE 2 Summary of the survival efﬁcacy induced by P. vivax CSP plus TRAP with vaccination regimens using vvTRAP, protein, or Rv21
in mice challenged by P. berghei sporozoitesa
Vaccine regimenb
No. of protected
mice/total no. of mice
Sterile
protection (%)
Median survival
(days)
Survival limit
(days)
Mean survival 
SD (days) SE
Naive 0/6 0 6.78 6.49–7.08 6.78 0.28 0.12
vvTRAP 0/6 0 7.28 6.46–7.62 7.12 2.5 0.21
Rv21 3/6 50 13.69 6.06–20.98 13.52 7.1 2.9
Rv21vvTRAP 6/6 100 20 20.0–20.0 20.0 0 0
vvTRAPMM 0/6 0 6.89 6.52–7.53 7.03 0.48 0.20
Rv21MM 6/6 100 20 20.0–20.0 20.0 0 0
Rv21vvTRAPMM 6/6 100 20 20.0–20.0 20.0 0 0
pCSMM 3/6 33 8.36 5.44–18.51 11.98 6.23 2.54
vvTRAPpCSMM 0/6 0 7.64 7.02–8.35 7.68 0.53 0.24
vvTRAPAdd 0/6 0 6.81 6.41–7.46 6.9 0.5 0.20
Rv21Add 5/6 83.3 20 12.7–23.2 20.0 0 2.03
Rv21vvTRAPAdd 6/6 100 20 20.0–20.0 20.0 0 0
aVaccinated BALB/c mice were challenged with 2,000 sporozoites of the PvCSP-PvTRAP 2207 cl1 strain, as described in the legend of Fig. 4.
bAdjuvants used were Matrix-M (MM) and AddaVax (Add).
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could contribute to reducing reactogenicity as this is the inevitable price for improving
immunogenicity in adjuvanted vaccines (33). Moreover, our results support the use of
fractional doses of a VLP due to a dose-sparing effect when Rv21 and viral vectors were
combined, and while an adjuvant affects the cost of a vaccine, replacing it with a viral
vector may not signiﬁcantly alter the total cost of a vaccination approach and gives an
opportunity to assess alternative methods to limit reactogenicity while improving the
breadth of responses, thus enhancing immunity against malaria.
Our results support the notion that protective immunity against malaria may require
harnessing humoral and cellular responses against multiple antigens (7), which has
been shown in earlier studies where a combination the two preerythrocytic antigens,
CSP and TRAP, has enhanced protection against mouse malaria in a P. berghei mouse
sporozoite challenge (8). Such studies stressed the importance of the protective effect
of monoclonal antibodies against CSP and how, at suboptimal doses, protection was
rescued by viral vector vaccination against P. berghei TRAP. In the current study, we
have conﬁrmed this observation using the P. vivax proteins as vaccine targets by
FIG 5 Assessment of vaccine efﬁcacy using a combination of Rv21 with viral-vectored vaccines expressing
P. vivax TRAP (vvTRAP) or an unrelated transgene (vvControl). (A) Table indicating the vaccination
components in an 8-week prime-boost regimen, utilized to compare the efﬁcacy against a sporozoite
challenge with a combination of a P. vivax VLP (Rv21), a P. falciparum VLP (R21) with vvTRAP, or an unrelated
nonmalaria antigen vvControl. (B) Survival of mice (n  6) after a sporozoite challenge with the vaccination
regimens described in panel A. (C) Titer of anti-PvCSP antibodies by Rv21 or a combination of Rv21 plus
vvTRAP. (D) Ex vivo IFN- responses against TRAP measured by ELISpot assay. SFU, spot-forming units.
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maximizing anti-CSP antibody responses through the use of the Rv21 VLP and T-cell
responses using viral vectors expressing TRAP. Similar observations have been made for
P. falciparum. In a recent phase IIa clinical trial (9), a leading P. falciparum malaria
vaccine was assessed for protective efﬁcacy against a sporozoite challenge. This
consisted of a CSP-based VLP RTS,S in combination with viral-vectored ME-TRAP. In that
study, the combination showed evidence of being more efﬁcacious (82.4%) than RTS,S
alone (75%). This demonstrates a difﬁculty also encountered in the design of the
present study: establishing that the combination of TRAP and CSP enhances efﬁcacy
requires that both regimens alone elicit suboptimal protection. A mathematical model
(34) predicts that combining an RTS,S vaccine of 50% efﬁcacy with a viral-vectored
ME-TRAP regime with 21% efﬁcacy would confer protective efﬁcacy of 97%. The murine
evidence presented here and elsewhere (16, 23) is consistent with this prediction and
suggests that a strategy of combining subunit vaccines could prove crucial in devel-
oping a malaria vaccine of the desired 75% efﬁcacy (35) and yet provide a dose-sparing
effect where improved efﬁcacy with low doses of vaccines could contribute to a
decrease in vaccine costs.
Our results also indicate that an improvement in protective efﬁcacy requires the
combination of Rv21 with vivax vvTRAP to act synergistically in order to completely
eliminate infection since the use of viral vectors expressing unrelated transgenes does
not produce improved immunity against malaria. This indicates that augmenting the
breadth of responses to multiple antigens plays an important role in the increase in
protective efﬁcacy seen here with Rv21 and vvTRAP coadministration. This supports the
observations made previously stressing the major challenge posed by the complexity
of the malaria parasite that transitions from extracellular to intracellular stages during
the life cycle in the mammalian host, thus requiring harnessing cellular and humoral
responses against more than one antigen to induce protective immunity (7).
It is possible that a CSP/TRAP combination regime without adjuvants could be used
in future P. vivax clinical trials, given that viral vectors have been shown here to possess
as potent an adjuvant effect as the other adjuvants tested. It remains to be seen
whether the adjuvanting effects of VLPs and viral vectors on each other in the absence
of adjuvant are recapitulated in phase I and II trials.
When considering the implications of these results on the choice of adjuvant for a
CSP/TRAP combination vaccine, we must also consider the long-term effects of adju-
vants on immune responses. Antigenic interference was not seen in the medium to
long term with Matrix-M or AddaVax in this study. Indeed, 150 days after priming,
anti-CSP titers were highest in Matrix-M-vaccinated groups. Given that the malaria
research community is aiming for a vaccine which remains 75% effective for 2 years
(35), longevity of protection may prove more important than short-term antigenic
effects on interference in the decision about the most appropriate adjuvant to use. In
this regard, Matrix-M and AddaVax are equally good in the induction of protective
immunity against malaria, at least in terms of antibody titers.
In summary, the combination of two P. vivax antigens, CSP and TRAP, using
appropriate platforms for each candidate (a VLP for CSP and viral vectors for TRAP),
improves protective efﬁcacy compared to use of either alone. Improved immunoge-
nicity and protective efﬁcacy was also seen with the use of AddaVax and Matrix-M
adjuvants in combination with Rv21. This study demonstrates the potential of com-
bining subunit antigens using suitable platforms as a method of enhancing the
protective efﬁcacy of malaria vaccines.
MATERIALS AND METHODS
Generation of DNA constructs and genotyping of the double-chimeric parasite line PvCSP/
PvTRAP. Two reference WT lines of P. berghei ANKA were used to construct a double-chimeric parasite:
the wild-type (WT) reference line cl15cy1 of P. berghei ANKA (36) and the reporter PbANKA parasite line
PbGFP-Luccon (676m1cl1). The PbGFP-Luccon parasite expresses a fusion protein of GFP (mutant 3) and
ﬁreﬂy luciferase (LUC-IAV) under the constitutive eef1a promoter and is selectable marker (SM) free (37).
The reporter cassette is integrated into the neutral 230p locus (Eukaryotic Pathogen Database [EuPathDB]
accession number PBANKA_030600). For details of PbGFP-Luccon, see the RMgm (Rodent Malaria genet-
ically modiﬁed) database (entry RMgm-29 [http://www.pberghei.eu/index.php?rmgm29]).
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For the generation and genotyping of the chimeric parasites, we used Swiss mice (OF1/ico, construct
242; 6 weeks old; 25 to 26 g) (Charles River). All animal experiments performed at the Leiden University
Medical Center (LUMC) were approved by the Animal Experiments Committee of the Leiden University
Medical Center (DEC 12042). The Dutch Experiments on Animals Act was established under European
guidelines (European Union directive no. 86/609/EEC regarding the Protection of Animals used for
Experimental and Other Scientiﬁc Purposes).
The double-chimeric line PvCSP-VK210/PvTRAP in which both the csp (EuPathDB accession number
PBANKA_040320) and the trap (EuPathDB accession number PBANKA_134980) CDSs of P. berghei were
replaced with csp (EuPathDB accession number PVX_119355) and trap (NCBI accession number
XM_001614097) genes of P. vivax was generated by replacing the Pbtrap gene with Pvtrap in a single
chimeric line in which the Pbcsp gene had been previously replaced by the VK210 allele of Pvcsp. The
single-chimeric line, PbANKA-PvCSP-VK210(r)PbCSP (line 2196cl1), had been generated using the gene
insertion/marker out (GIMO)-based transfection technology as described previously (15) and is free of a
drug-selectable marker. In addition, it contains the GFP-luciferase fusion gene as a reporter. The absence
of a drug-selectable marker allowed the replacement of the Pbtrap gene with the Pvtrap gene in parasites
of the PbANKA-PvCSP-VK210(r)PbCSP line in a single transfection experiment using the trap replacement
construct described by Bauza et al. (16). This construct contains a synthetic trap allele composed of the
protein coding sequence of P. vivax TRAP (NCBI accession number XM_001614097) from the Salvador I
strain, which was codon optimized for expression in P. berghei using GeneOptimizer software. In addition,
this construct contains a positive/negative selectable marker (SM) cassette with the human dhfr and
yeast fcu (hdhfr::yfcu) fusion gene. Transfection of PbANKA-PvCSP-VK210(r)PbCSP parasites with the Pvtrap
replacement construct and positive selection with pyrimethamine were performed using standard
methods for transfection of P. berghei (36). This resulted in selection of double-chimeric parasites (line
2207). Selected double-chimeric parasites were cloned by the method of limiting dilution (38), resulting
in the PbANKA-PvCSP-VK210(r)PbCSPPvTRAP(r)PbTRAPSM line (2207 cl3). Correct integration of the
constructs into the genome of the double-replacement gene [DRG] chimeric parasite was analyzed by
diagnostic PCR analysis on gDNA and Southern analysis of pulsed-ﬁeld gel electrophoresis (PFGE)-
separated chromosomes as described previously (36). Primers used for PCR genotyping are listed in Table
S1 in the supplemental material.
Subsequently, we recycled the positive-negative SM cassette from the parasites of line 2207 cl3 by
applying negative selection by providing 5-ﬂuorocytosine (5-FC) in the drinking water of mice (39).
Negative selection and removal of the hdhfr::yfcu SM cassette resulted in selection of PbANKA-PvCSP-
VK210(r)PbCSPPvTRAP(r)PbTRAP parasites (2207 cl3m0). Selected parasites were cloned by the method of
limiting dilution (38) resulting in parasite line 2207 cl3m0cl1. This double-chimeric line PbANKA-PvCSP-
VK210(r)PbCSPPvTRAP(r)PbTRAP is referred to as PvCSP-VK210/PvTRAP parasites.
Correct integration of the constructs into the genome of double-chimeric parasites was analyzed by
diagnostic PCR analysis on gDNA and Southern analysis of pulsed-ﬁeld gel electrophoresis (PFGE)-separated
chromosomes as described previously (37). Primers used for PCR genotyping are listed in Table S1.
Phenotyping of the double-chimeric parasites. Growth of blood stages of the reporter and
chimeric P. berghei parasites was determined during the cloning period, as described previously (36, 40).
Feeding of A. stephensi mosquitoes, determination of oocyst production, and sporozoite collection were
performed as described previously (40). Expression of PvCSP-VK210 and PvTRAP antigens in sporozoites
of the chimeric parasites was analyzed by immunoﬂuorescence staining assay (IFA), using two anti-P.
vivax antigen monoclonal antibodies, anti-PvCSP-VK210 (obtained through BEI Resources, NIAID, NIH;
hybridoma 2E10.E9 anti-Plasmodium vivax circumsporozoite protein, catalogue no. MRA-185, contributed
by Elizabeth Nardin) (diluted 200 times) or anti-PvTRAP polyclonal antibodies elicited by viral vector
vaccination. In addition we used anti-PbCSP 3D11 (41) antibodies as a control (diluted 1,000 times) and
serum from mice vaccinated with ChAd63-MVA expressing PbTRAP (diluted 50 times). Puriﬁed sporo-
zoites were ﬁxed with 4% paraformaldehyde in phosphate-buffered saline (PBS) for 20 min on ice,
washed three times with PBS, and blocked with 20 l of 10% fetal calf serum (FCS) plus 1% bovine serum
albumin (BSA) in PBS for 30 min at room temperature. The excess blocking medium was removed,
followed by the addition of 20 to 25 l of primary monoclonal antibody in 10% FCS–1% BSA in PBS
(blocking medium) for 1 to 2 h at room temperature or overnight at 4°C. After incubation, the primary
antibody was removed, and the slides were washed three times with PBS, followed by staining with a
secondary antibody, Alexa Fluor 488 goat anti-mouse IgG (catalog number A-11001; Life Technologies),
diluted 800 times in 10% FCS–1% BSA in PBS (blocking medium) for 1 h at room temperature. After three
washes with PBS, nuclei were stained with 2% Hoechst-33342 (4082S; Cell Signaling Technology) in PBS
for 10 min at room temperature, washed twice with PBS, and left to air dry; this was followed by the
addition of ﬂuorescence mounting medium (code S3023; Dako) before complete dry out. Coverslips were
mounted onto the slides, and the slides were sealed with nail polish and left to dry overnight in the dark.
The parasites in both blue and green channels were analyzed using a DMI-300B Leica ﬂuorescence
microscope, and images were processed using ImageJ software.
Viral vector vaccines. Mice were primed with simian adenoviral vector 63 (ChAd63) encoding
PvTRAP, as described earlier (16), and PvCSP VK210 (15) and 8 weeks later boosted with modiﬁed vaccinia
virus strain Ankara (MVA) carrying the same transgene at a dose of 1  107 PFU (15, 16). A control viral
vector was designed and constructed to express Tc24-IMX (a Trypanosoma cruzi antigen; GenBank
accession number U70035.1). Brieﬂy, the Tc24 gene from Trypanosoma cruzi was synthesized by GeneArt
(Germany) and cloned into the plasmid pMono2 using the restriction sites Acc651 and BamHI. Tc24 was
cloned into ChAd63, and the presence of the Tc24 gene was conﬁrmed by PCR, while the integrity of the
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antigenic DNA sequence and absence of contaminating adenovirus were conﬁrmed by PCR followed by
restriction fragment length polymorphism (RFLP).
The virus was titrated to obtain the number of infectious units (IU) per milliliter and assayed by
spectrophotometry to quantify the number of virus particles per milliliter. The sterility of the virus was
also conﬁrmed by inoculation of tryptic soy broth (TSB) with 10 l of puriﬁed virus and incubation for
3 days at 35°C. Quality control tests indicated infectious units by titration of 1.0E11 IU/ml, a virus
particle (VP) concentration of 7.2E12 VP/ml, and a particle/infectious units (P/I) ratio of 70.3 at a dose
of 1  108 IU. To construct MVA-Tc24, the gene was cloned into a plasmid (p2773) suitable for MVA
recombination. The virus and plasmid were recombined, and the cell lysate was harvested and used at
1:10 and 1:50 dilutions to infect chicken embryonic ﬁbroblasts (CEF). CEF cells were MoFlo sorted into
96-well plates. Recombinant virus was puriﬁed by selecting individual plaques to be subsequently
cultured to eliminate parental virus, and purity was determined through ampliﬁcation of the DNA
sequence by PCR followed by RFLP. The virus was then ampliﬁed to conﬁrm the presence of the antigen
in question and lack of original, parental virus expressing the red ﬂuorescent protein in the ﬁnal stock.
Sterility of the virus was conﬁrmed by inoculation of TSB with 10 l of puriﬁed virus and incubation for
3 days at 35°C. The numbers of PFU were calculated upon titration, yielding 4.6 108 PFU/ml. Additional
control viral vectors expressing ovalbumin (Ova) and GFP have been published previously, such as
AdHu5 Ova (42), ChAd63 Ova, and MVA GFP (8).
Rv21 virus-like particle vaccine. Rv21 is a chimeric fusion of the central repeat regions of
PvCSP-VK210 (NCBI accession no: P08677) and VK247 (NCBI accession no: M69059) and the C terminus
of PvCSP-VK210, fused to the N terminus of hepatitis B surface antigen (HepBsAg) and expressed in Pichia
pastoris (15). A gene containing a chimeric CSP sequence comprising the repeat regions VK210 and
VK247, followed by the C-terminal sequence (210/247C), was designed to be fused to HepBsAg. This VLP
was described previously (15). Characterization of the Rv21 VLP was made by Western blotting using
anti-PvCSP-VK210 (obtained through BEI Resources, NIAID, NIH; hybridoma 2E10.E9 anti-Plasmodium
vivax circumsporozoite protein, catalogue mo. MRA-185, contributed by Elizabeth Nardin) and anti-
PvCSP-VK247 (obtained through BEI Resources, NIAID, NIH; hybridoma 2F2 anti-Plasmodium vivax
circumsporozoite protein, catalogue no. MRA-184, contributed by Elizabeth Nardin) primary mouse
antibodies, diluted in 3% BSA-PBS to 1:200, 1:20,000, and 1:20,000. A secondary donkey anti-mouse
alkaline phosphatase (AP) conjugate in 3% BSA-PBS and Sigmafast BCIP/NBT (5-bromo-4-chloro-3-
indolylphosphate/nitroblue tetrazolium) tablets (Sigma-Aldrich) were used for development.
Vaccination. All viral vector, VLP, and protein vaccines were administered intramuscularly in
endotoxin-free PBS. Combinations of vaccines were mixed prior to administration (called coadministra-
tion in this paper) unless otherwise stated.
Animals. Female inbred BALB/c (H-2d) mice were used for the assessment of immunogenicity and
protection after challenge. Six to 8 mice per group were used for the studies. Tuck-ordinary (TO) outbred mice
were used for parasite production and transmission. The mice were purchased from Harlan (United Kingdom).
Ethics statement. All animals and procedures were used in accordance with the terms of the United
Kingdom Home Ofﬁce Animals Act Project License. The procedures were approved by the University of
Oxford Animal Care and Ethical Review Committee (PPL 30/2414).
Protein production. PvTRAP protein used for enzyme-linked immunosorbent assays (ELISAs) was
prepared using HEK293 cells as described earlier (16, 43). PvCSP was produced as described earlier (15).
Use of Ova protein was described earlier (44).
Ex vivo IFN- ELISpot assay. Ex vivo IFN- ELISpot assays were carried out using peripheral blood
mononuclear cells (PBMCs) isolated from blood as previously described (8, 16). Twenty-amino-acid peptides
from PvTRAP previously shown to be immunodominant in BALB/c mice (ITKVIPMLNGLINSLSLSRD) (16)
(ThinkPeptides) or peptide pools of 20 amino acids representing the full-length protein and overlapping by
10 amino acids (Mimotopes) were used to stimulate PBMCs at a ﬁnal concentration of 5 g/ml. MAIP ELISpot
plates (Millipore) were used to plate cells. Anti-mouse IFN-monoclonal antibody and development reagents
were used according to the manufacturer’s speciﬁcations (Mabtech).
Whole IgG ELISA, avidity ELISA, and IgG subclass ELISA. Enzyme-linked immunosorbent assays
(ELISAs) measuring total IgG were carried out as described previously (45), and serum antibody endpoint
titers were taken as the x axis intercept of the dilution curve at an absorbance value 3 standard deviations
greater than the optical density at 405 nm (OD405) for serum from a naive mouse.
For standard-curve ELISAs, plates were prepared as for endpoint ELISAs, and then serum was diluted
between 1:500 and 1:20,000 in PBS-Tween before application in triplicate at 50 l/well. A standard curve
was produced in duplicate on each plate by 3-fold serial dilution from 1:750 (for PvCSP) or 2-fold serial
dilution from 1:100 (for PvTRAP) through 10 wells using stock sera from Rv21 (15) and Ad-M PvTRAP-
vaccinated mice (16). Following 2 h of incubation at room temperature, plates were treated as for
endpoint ELISAs, with plates scanned at 405 nm after 14 min for PvCSP-coated plates and 18 min for
PvTRAP-coated plates. MARS (Multivariate Adaptive Regression Splines) software was used to obtain
four-parameter logistic values of the standard curve on each plate for analysis and expression of serum
OD values in terms of arbitrary ELISA units (EU) relative to the standard curve.
For avidity ELISAs, standard-curve ELISAs were performed as described above except that after 2 h of
incubation of the serum at room temperature, plates were washed six times in PBS-Tween, and 100 l of 7
M urea was added to serum wells for 10 min. Plates were then washed six times in PBS-Tween, and the
standard-curve ELISA was carried out as before. The avidity index was calculated as the percentage of log10
EU of urea-treated compared to untreated serum samples, following the procedure described in (46).
For IgG subclass ELISAs, standard-curve ELISAs were performed at the end of the study, day 275,
using a Bio-Rad Mouse Typer Sub-Isotyping kit according to the manufacturer’s protocol (Bio-Rad) with
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the modiﬁcation that after serum incubation, subclass-speciﬁc rabbit anti-mouse IgG was applied at 50
l per well in triplicate. Serum for a standard curve was incubated with kappa-chain-speciﬁc IgG. After
1 h of incubation, plates were washed six times in PBS-Tween, and goat anti-rabbit horseradish
peroxidase conjugate was applied (50 l/well; 1:3,000). After 1 h plates were washed six times in
PBS-Tween and developed for 14 min (PvCSP-coated plates) or 18 min (PvTRAP-coated plates) using 100
l/well peroxidase substrate solution (Bio-Rad). Reactions were stopped by the addition of 100 l/well
of 2% oxalic acid.
Parasite production and challenge. Wild-type and transgenic parasites used to challenge mice
were produced at the Jenner Institute insectary. Female Anopheles stephensi mosquitoes were fed on
infected TO mice. Exﬂagellation was ﬁrst conﬁrmed, and mosquitoes were exposed to anesthetized
infected mice for 15 min. The mosquitoes were then maintained for 21 days in a humidiﬁed incubator
at a temperature of 19 to 21°C on a 12-h night-day cycle and fed with a fructose–p-aminobenzoic acid
(PABA) solution. At 21 days salivary glands were dissected from mosquitoes into Schneider’s medium
(Pan Biotech), and sporozoites were gently liberated using a glass homogenizer. Sporozoites were diluted
to the required concentration for 100 l of intravenous injection into the tail vein of the mouse.
Adjuvants. When used, adjuvants were mixed and coinjected with vaccines. AddaVax was used at
25 l per dose; Matrix-M was used at 5 g per dose. AddaVax (InvivoGen) was kindly provided by the
Jenner Institute adjuvant bank by Anita Milicic, and Matrix-M was obtained from Novavax AB.
Statistical model for parasitemia prediction. To extrapolate the liver-to-blood parasite load or
predict the time to 1% blood stage infection, a linear regression model was used as described previously
(47). Brieﬂy, blood parasite counts were obtained for 3 to 5 consecutive days starting on day 4 after
challenge. Blood smears were stained with Giemsa stain, and percentages of parasitemia were calculated
in all animals. The log10 value of the calculated percentage of parasitemia was plotted against time after
challenge, and Prism, version 6 (GraphPad Software), for Mac OS X was used for generating a linear
regression model on the linear part of the blood stage growth curve.
Statistical analysis. For all statistical analyses, GraphPad Prism, version 6.0, for Mac OS X was used
unless otherwise indicated. Prior to statistical analysis to compare two or more populations, the
Kolmogorov-Smirnov test for normality was used to determine whether the values followed a Gaussian
distribution. An unpaired t test was employed to compare two normally distributed groups, whereas a
Mann-Whitney rank test was used to compare two nonparametric groups. If more than two groups were
present, nonparametric data were compared using a Kruskal-Wallis test with Dunn’s multiple-comparison
posttest, whereas normally distributed data were analyzed by one-way analysis of variance (ANOVA) with
Tukey’s multiple-comparison posttest. Correlation strength was assessed using either Pearson’s or
Spearman’s test, as indicated in Results. Kaplan-Meier survival curves were used to represent protective
efﬁcacy against challenge with P. berghei parasite lines. All ELISA titers were log10 transformed before
analysis.
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